Bone biopsy and densitometry findings in a child with Camurati-Engelmann disease

被引:14
作者
Bondestam, Jonas
Mayranpaa, Mervi K.
Ikegawa, Shiro
Marttinen, Eino
Kroger, Heikki
Makitie, Outi
机构
[1] Hosp Children & Adolescents, Dept Pediat, FI-00029 Helsinki, Finland
[2] Hosp Children & Adolescents, Dept Surg, FI-00029 Helsinki, Finland
[3] RIKEN, SNP Res Ctr, Lab Bone & joint Dis, Tokyo 108, Japan
[4] Univ Kuopio, Kuopio Univ Hosp, Dept Orthopaed & Traumatol, Kuopio, Finland
[5] Univ Helsinki Hosp, Med Imaging Ctr, Helsinki, Finland
[6] Univ Kuopio, Kuopio Univ Hosp, Dept Orthopaed & traumatol, Bone & Cartilage Res Unit, FIN-70211 Kuopio, Finland
关键词
bisphosphonate; Camurati-Engelmann disease; osteoporosis;
D O I
10.1007/s10067-006-0511-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Progressive diaphyseal dysplasia (MIM 131300), also known as Camurati-Engelmann disease (CED), is a rare autosomal dominant craniotubular dysplasia caused by mutations in the transforming growth factor beta1 (TGF-beta 1) gene. Radiographs of the long bones of a 9-year-old boy presenting with waddling gait, muscular weakness, underweight, and severe skeletal pain showed symmetric diaphyseal cortical thickening pathognomonic for CED. The diagnosis was verified by detecting a mutation in exon 4 of the TGF-beta 1 gene. Full body bone mineral densitometry studies performed before treatment with prednisolone were indicative for osteoporosis (Z-scores for the lumbar spine and femoral neck -2.3 and -3.2, respectively). A transiliac bone biopsy showed markedly reduced trabecular bone volume. Oral prednisolone was initiated, and subsequently, pamidronate infusions were commenced in an attempt to prevent progression of osteoporosis. To our knowledge, this is the first time bone biopsy and bone mineral densitometry studies have been performed and bisphosphonate treatment evaluated in a child with CED.
引用
收藏
页码:1773 / 1777
页数:5
相关论文
共 19 条
[1]  
Camurati M., 1922, CHIR ORG MOVIMENTO, V6, P662
[2]  
CANALIS E, 2000, CURR OPIN ENDOCRINOL, V7, P320
[3]   Camurati-Engelmann disease:: failure of response to bisphosphonates:: report of two cases [J].
Castro, GRW ;
Appenzeller, S ;
Marques-Neto, JF ;
Bértolo, MB ;
Samara, AM ;
Coimbra, I .
CLINICAL RHEUMATOLOGY, 2005, 24 (04) :398-401
[4]  
Chérie-Ligniére G, 1999, CLIN EXP RHEUMATOL, V17, P264
[5]  
ENGELMANN G, 1929, ROFO FORTSCHR RONTG, V39, P1101
[6]   Normative data for iliac bone histomorphometry in growing children [J].
Glorieux, FH ;
Travers, R ;
Taylor, A ;
Bowen, JR ;
Rauch, F ;
Norman, M ;
Parfitt, AM .
BONE, 2000, 26 (02) :103-109
[7]   TYPE-BETA TRANSFORMING GROWTH-FACTOR CONTROLS THE ADIPOGENIC DIFFERENTIATION OF 3T3 FIBROBLASTS [J].
IGNOTZ, RA ;
MASSAGUE, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (24) :8530-8534
[8]   Scintigraphic evaluation of pamidronate and corticosteroid therapy in a patient with progressive diaphyseal dysplasia (Camurati-Engelmann disease) [J].
Inaoka, T ;
Shuke, N ;
Sato, J ;
Ishikawa, Y ;
Takahashi, K ;
Aburano, T ;
Makita, Y .
CLINICAL NUCLEAR MEDICINE, 2001, 26 (08) :680-682
[9]   Mutations in the gene encoding the latency-associated peptide of TGF-β1 cause Camurati-Engelmann disease [J].
Janssens, K ;
Gershoni-Baruch, R ;
Guañabens, N ;
Migone, N ;
Ralston, S ;
Bonduelle, M ;
Lissens, W ;
Van Maldergem, L ;
Vanhoenacker, F ;
Verbruggen, L ;
Van Hul, W .
NATURE GENETICS, 2000, 26 (03) :273-275
[10]   Camurati-Engelmann disease:: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment [J].
Janssens, K ;
Vanhoenacker, F ;
Bonduelle, M ;
Verbruggen, L ;
Van Maldergem, L ;
Ralston, S ;
Guañabens, N ;
Migone, N ;
Wientroub, S ;
Divizia, MT ;
Bergmann, C ;
Bennett, C ;
Simsek, S ;
Melançon, S ;
Cundy, T ;
Van Hul, W .
JOURNAL OF MEDICAL GENETICS, 2006, 43 (01) :1-11